Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Vitamin K supplementation and arterial calcification in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Levy-Schousboe, K, Frimodt-Møller, M, Hansen, D, Peters, CD, Kjærgaard, KD, Jensen, JD, Strandhave, C, Elming, H, Larsen, CT, Sandstrøm, H, Brasen, CL, Schmedes, A, Madsen, JS, Jørgensen, NR, Frøkjær, JB, Frandsen, NE, Petersen, I & Marckmann, P 2021, 'Vitamin K supplementation and arterial calcification in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial', Clinical kidney journal, bind 14, nr. 9, s. 2114-2123. https://doi.org/10.1093/ckj/sfab017

APA

Levy-Schousboe, K., Frimodt-Møller, M., Hansen, D., Peters, C. D., Kjærgaard, K. D., Jensen, J. D., Strandhave, C., Elming, H., Larsen, C. T., Sandstrøm, H., Brasen, C. L., Schmedes, A., Madsen, J. S., Jørgensen, N. R., Frøkjær, J. B., Frandsen, N. E., Petersen, I., & Marckmann, P. (2021). Vitamin K supplementation and arterial calcification in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial. Clinical kidney journal, 14(9), 2114-2123. https://doi.org/10.1093/ckj/sfab017

CBE

Levy-Schousboe K, Frimodt-Møller M, Hansen D, Peters CD, Kjærgaard KD, Jensen JD, Strandhave C, Elming H, Larsen CT, Sandstrøm H, Brasen CL, Schmedes A, Madsen JS, Jørgensen NR, Frøkjær JB, Frandsen NE, Petersen I, Marckmann P. 2021. Vitamin K supplementation and arterial calcification in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial. Clinical kidney journal. 14(9):2114-2123. https://doi.org/10.1093/ckj/sfab017

MLA

Vancouver

Author

Levy-Schousboe, Karin ; Frimodt-Møller, Marie ; Hansen, Ditte ; Peters, Christian Daugaard ; Kjærgaard, Krista Dybtved ; Jensen, Jens Dam ; Strandhave, Charlotte ; Elming, Hanne ; Larsen, Carsten Toftager ; Sandstrøm, Hanne ; Brasen, Claus Lohman ; Schmedes, Anne ; Madsen, Jonna Skov ; Jørgensen, Niklas Rye ; Frøkjær, Jens Brøndum ; Frandsen, Niels Erik ; Petersen, Inge ; Marckmann, Peter. / Vitamin K supplementation and arterial calcification in dialysis : results of the double-blind, randomized, placebo-controlled RenaKvit trial. I: Clinical kidney journal. 2021 ; Bind 14, Nr. 9. s. 2114-2123.

Bibtex

@article{139743fa4445461d86a3db7c0967b9cf,
title = "Vitamin K supplementation and arterial calcification in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial",
abstract = "Background: Arterial calcification is associated with cardiovascular mortality in dialysis patients. Active matrix Gla protein (MGP) is a vitamin K-dependent inhibitor of arterial calcification. Elevated plasma concentrations of inactive MGP, i.e. dephosphorylated-uncarboxylated MGP (dp-ucMGP), are prevalent in dialysis patients. MGP inactivity might contribute to arterial calcification. We investigated whether vitamin K supplementation had an effect on arterial calcification in chronic dialysis patients.Methods: In a 2-year, double-blind, placebo-controlled intervention trial, 48 dialysis patients were randomized to vitamin K [menaquinone-7 (MK-7), 360 µg daily] or placebo. MK-7 in serum and dp-ucMGP in plasma were used to assess vitamin K status. Carotid-femoral pulse wave velocity (cfPWV) and scores of coronary arterial calcification (CAC) and abdominal aortic calcification (AAC) were used to assess arterial calcification.Results: Thirty-seven participants completed Year 1, and 21 completed Year 2. At Year 2, serum MK-7 was 40-fold higher, and plasma dp-ucMGP 40% lower after vitamin K supplementation compared with placebo {mean dp-ucMGP difference: -1380 pmol/L [95% confidence interval (CI) -2029 to -730]}. There was no significant effect of vitamin K supplementation on cfPWV [mean difference at Year 2: 1.2 m/s (95% CI -0.1 to 2.4)]. CAC Agatston score increased significantly in vitamin K supplemented participants, but was not significantly different from placebo [mean difference at Year 2: 664 (95% CI -554 to 1881)]. AAC scores increased in both groups, significantly so within the placebo group at Year 1, but with no significant between-group differences.Conclusions: Vitamin K supplementation improved vitamin K status, but did not hinder or modify the progression of arterial calcification in dialysis patients.",
keywords = "chronic kidney disease, coronary arterial calcification, menaquinone-7, pulse wave velocity",
author = "Karin Levy-Schousboe and Marie Frimodt-M{\o}ller and Ditte Hansen and Peters, {Christian Daugaard} and Kj{\ae}rgaard, {Krista Dybtved} and Jensen, {Jens Dam} and Charlotte Strandhave and Hanne Elming and Larsen, {Carsten Toftager} and Hanne Sandstr{\o}m and Brasen, {Claus Lohman} and Anne Schmedes and Madsen, {Jonna Skov} and J{\o}rgensen, {Niklas Rye} and Fr{\o}kj{\ae}r, {Jens Br{\o}ndum} and Frandsen, {Niels Erik} and Inge Petersen and Peter Marckmann",
note = "{\textcopyright} The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA.",
year = "2021",
month = sep,
doi = "10.1093/ckj/sfab017",
language = "English",
volume = "14",
pages = "2114--2123",
journal = "Clinical kidney journal",
issn = "2048-8505",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - Vitamin K supplementation and arterial calcification in dialysis

T2 - results of the double-blind, randomized, placebo-controlled RenaKvit trial

AU - Levy-Schousboe, Karin

AU - Frimodt-Møller, Marie

AU - Hansen, Ditte

AU - Peters, Christian Daugaard

AU - Kjærgaard, Krista Dybtved

AU - Jensen, Jens Dam

AU - Strandhave, Charlotte

AU - Elming, Hanne

AU - Larsen, Carsten Toftager

AU - Sandstrøm, Hanne

AU - Brasen, Claus Lohman

AU - Schmedes, Anne

AU - Madsen, Jonna Skov

AU - Jørgensen, Niklas Rye

AU - Frøkjær, Jens Brøndum

AU - Frandsen, Niels Erik

AU - Petersen, Inge

AU - Marckmann, Peter

N1 - © The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA.

PY - 2021/9

Y1 - 2021/9

N2 - Background: Arterial calcification is associated with cardiovascular mortality in dialysis patients. Active matrix Gla protein (MGP) is a vitamin K-dependent inhibitor of arterial calcification. Elevated plasma concentrations of inactive MGP, i.e. dephosphorylated-uncarboxylated MGP (dp-ucMGP), are prevalent in dialysis patients. MGP inactivity might contribute to arterial calcification. We investigated whether vitamin K supplementation had an effect on arterial calcification in chronic dialysis patients.Methods: In a 2-year, double-blind, placebo-controlled intervention trial, 48 dialysis patients were randomized to vitamin K [menaquinone-7 (MK-7), 360 µg daily] or placebo. MK-7 in serum and dp-ucMGP in plasma were used to assess vitamin K status. Carotid-femoral pulse wave velocity (cfPWV) and scores of coronary arterial calcification (CAC) and abdominal aortic calcification (AAC) were used to assess arterial calcification.Results: Thirty-seven participants completed Year 1, and 21 completed Year 2. At Year 2, serum MK-7 was 40-fold higher, and plasma dp-ucMGP 40% lower after vitamin K supplementation compared with placebo {mean dp-ucMGP difference: -1380 pmol/L [95% confidence interval (CI) -2029 to -730]}. There was no significant effect of vitamin K supplementation on cfPWV [mean difference at Year 2: 1.2 m/s (95% CI -0.1 to 2.4)]. CAC Agatston score increased significantly in vitamin K supplemented participants, but was not significantly different from placebo [mean difference at Year 2: 664 (95% CI -554 to 1881)]. AAC scores increased in both groups, significantly so within the placebo group at Year 1, but with no significant between-group differences.Conclusions: Vitamin K supplementation improved vitamin K status, but did not hinder or modify the progression of arterial calcification in dialysis patients.

AB - Background: Arterial calcification is associated with cardiovascular mortality in dialysis patients. Active matrix Gla protein (MGP) is a vitamin K-dependent inhibitor of arterial calcification. Elevated plasma concentrations of inactive MGP, i.e. dephosphorylated-uncarboxylated MGP (dp-ucMGP), are prevalent in dialysis patients. MGP inactivity might contribute to arterial calcification. We investigated whether vitamin K supplementation had an effect on arterial calcification in chronic dialysis patients.Methods: In a 2-year, double-blind, placebo-controlled intervention trial, 48 dialysis patients were randomized to vitamin K [menaquinone-7 (MK-7), 360 µg daily] or placebo. MK-7 in serum and dp-ucMGP in plasma were used to assess vitamin K status. Carotid-femoral pulse wave velocity (cfPWV) and scores of coronary arterial calcification (CAC) and abdominal aortic calcification (AAC) were used to assess arterial calcification.Results: Thirty-seven participants completed Year 1, and 21 completed Year 2. At Year 2, serum MK-7 was 40-fold higher, and plasma dp-ucMGP 40% lower after vitamin K supplementation compared with placebo {mean dp-ucMGP difference: -1380 pmol/L [95% confidence interval (CI) -2029 to -730]}. There was no significant effect of vitamin K supplementation on cfPWV [mean difference at Year 2: 1.2 m/s (95% CI -0.1 to 2.4)]. CAC Agatston score increased significantly in vitamin K supplemented participants, but was not significantly different from placebo [mean difference at Year 2: 664 (95% CI -554 to 1881)]. AAC scores increased in both groups, significantly so within the placebo group at Year 1, but with no significant between-group differences.Conclusions: Vitamin K supplementation improved vitamin K status, but did not hinder or modify the progression of arterial calcification in dialysis patients.

KW - chronic kidney disease

KW - coronary arterial calcification

KW - menaquinone-7

KW - pulse wave velocity

U2 - 10.1093/ckj/sfab017

DO - 10.1093/ckj/sfab017

M3 - Journal article

C2 - 34476095

VL - 14

SP - 2114

EP - 2123

JO - Clinical kidney journal

JF - Clinical kidney journal

SN - 2048-8505

IS - 9

ER -

ID: 67500744